DadFinStart your free week
DadFin › Stocks › Healthcare › CRL

Charles River Laboratories Interna (CRL) stock score

Healthcare · Diagnostics & Research · United States

$301.79 ▲ +1.27% today

71.0
Dad Score, out of 100
good

Charles River Laboratories Interna (CRL) is a Diagnostics & Research company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 71.0 out of 100 on the Dad Score, a good reading that places the business ahead of 71% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #248 of 974. Its strongest axes are valuation, price action and conviction; its weakest are growth and risk.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Above average
Quality
Average
Growth
Weak
Price action
Above average
Risk
Weak
Conviction
Above average
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)22.8×
Dividend yield0.00%
Return on capital0.1%
Operating margin15.1%
Revenue growth (YoY)-0.9%
FCF yield3.3%
Net debt / EBITDA3.35×
Piotroski F-Score5 / 9
52-week change+65.9%
Market cap$13.9B
Next earningsNov 4, 2026

What subscribers see on CRL

Start your free weekSubscriber? Open the full research →

Diagnostics & Research peers

StockCompanyDad ScoreBandMarket cap
TMOThermo Fisher Scientific Inc.77.0good$242.1B
DHRDanaher Corporation79.6good$150.5B
NTRANatera, Inc.86.1strong$59.1B
AAgilent Technologies, Inc.79.9good$47.3B
IQVIQVIA Holdings Inc.82.3good$42.5B
WATWaters Corporation78.8good$41.7B
ILMNIllumina, Inc.35.1weak$41.2B
IDXXIDEXX Laboratories, Inc.90.1strong$40.9B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.